Statin Therapy Impacts on Ischemic Stroke Outcomes

Statins, or HMG-CoA reductase inhibitors, have established benefits in primary and secondary prevention of cerebrovascular events by lowering low-density lipoprotein cholesterol and stabilising atheromatous plaques. Beyond lipid reduction, statins exert pleiotropic actions including improved endothelial function, attenuation of oxidative stress, modulation of inflammatory cascades and promotion of neurovascular repair. In acute ischaemic stroke, pre-treatment or early initiation of statin therapy has been associated with reduced infarct volumes, milder neurological deficits and favourable functional recovery at three months. Experimental studies reveal that statins inhibit key transcription factors such as nuclear factor-kappa B, minimise microglial activation and support mitochondrial biogenesis in peri-infarct neurons. In reperfusion strategies—both intravenous thrombolysis and endovascular thrombectomy—statin use before or soon after recanalisation appears to enhance reperfusion success, limit haemorrhagic complications and improve long-term independence as measured by standard scales. These findings underscore the global relevance of integrating statin protocols into acute stroke pathways, offering accessible and cost-effective adjunctive neuroprotection that may translate into reduced disability and mortality worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Statin Therapy Impacts on Ischemic Stroke Outcomes publication trend

The graph below shows the total number of articles in statin therapy impacts on ischemic stroke outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Statin therapy: Inhibition of HMG-CoA reductase to lower cholesterol and exert vascular–neuroprotective effects.

Ischaemic stroke: Cerebral infarction resulting from arterial occlusion and subsequent lack of blood flow.

Modified Rankin Scale (mRS): A scale (0–6) assessing degree of disability or dependence after stroke.

National Institutes of Health Stroke Scale (NIHSS): A quantitative tool to measure stroke-related neurological deficit.

Intravenous thrombolysis (IVT): Administration of clot-dissolving agents via a peripheral vein in acute stroke.

Endovascular thrombectomy (EVT): Mechanical removal of an intracranial clot using catheter-based devices.

Nuclear factor-kappa B (NF-κB): A transcription factor family regulating inflammation, apoptosis and cell survival in stroke.

References

1. The Effect of Simvastatin on the Dynamics of NF-κB-Regulated Neurodegenerative and Neuroprotective Processes in the Acute Phase of Ischemic Stroke. Molecular Neurobiology (2023).
2. HMG‐CoA Reductase Inhibitors Attenuate Neuronal Damage by Suppressing Oxygen Glucose Deprivation‐Induced Activated Microglial Cells. Neural Plasticity (2019).
3. Rosuvastatin Improves Neurite Outgrowth of Cortical Neurons against Oxygen-Glucose Deprivation via Notch1-mediated Mitochondrial Biogenesis and Functional Improvement. Frontiers in Cellular Neuroscience (2018).
4. Low dose statins improve prognosis of ischemic stroke patients with intravenous thrombolysis. BMC Neurology (2021).
5. Impact of Prior Statin Use on Reperfusion Rate and Stroke Outcomes in Patients Receiving Endovascular Treatment. Journal of Clinical Medicine (2021).